Trial · NCT06219915

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm

NCT06219915, Phase 1, Phase 2, Completed, University of Michigan; results first posted 2025-06-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm. Trials, record NCT06219915. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06219915

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
NCT number: NCT06219915
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 13 participants, actual
Lead sponsor: University of Michigan
Conditions: Parkinsonian Signs in Older Persons
Interventions: Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1, Placebo 2
First posted: 2024-01-23
Last updated: 2025-06-17
Results first posted: 2025-06-17

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Average Gait Speed	Baseline and post-intervention (7-13 days after beginning supplement)	Average gait speed as measured using wearable sensors and while walking on a sensor mat. Measured in meters per second.
Secondary	Parkinson's Disease (PD)-Cognitive Rating Scale Score	Baseline and post-intervention (7-13 days after beginning supplement)	Cognitive scale designed to capture impairments in cognitive function in Parkinson's disease. (Scoring: 0-134, with higher scores indicating better performance).
Secondary	Mean of Number of Incorrect Responses on the Stroop Color Word Stepping Test	Baseline and post-intervention (7-13 days after beginning supplement)	During this test, subjects make steps based on congruent (stimulus prompts the stepping response) and incongruent (stimulus prompts inhibition of the stepping response) arrows and sounds. This will be used to compare the number of incorrect responses (stepping) from pre and post intervention visits to determine if inhibitory control improves (indicated by decrease in number of incorrect responses). The test included 8 total opportunities for response.
Secondary	Mean of Reaction Time During the Stroop Color Word Stepping Test	Baseline and post-intervention (7-13 days after beginning supplement)	During this test, subjects make steps based on congruent (stimulus prompts the stepping response) and incongruent (stimulus prompts inhibition of the stepping response) arrows and sounds. This will be used to compare the response time between pre and post intervention to determine if reaction time improves.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Average Gait Speed	Baseline and post-intervention (7-13 days after beginning supplement)	meters per second	MEAN
SECONDARY	Parkinson's Disease (PD)-Cognitive Rating Scale Score	Baseline and post-intervention (7-13 days after beginning supplement)	score on a scale	MEAN
SECONDARY	Mean of Number of Incorrect Responses on the Stroop Color Word Stepping Test	Baseline and post-intervention (7-13 days after beginning supplement)	Incorrect Responses	MEAN
SECONDARY	Mean of Reaction Time During the Stroop Color Word Stepping Test	Baseline and post-intervention (7-13 days after beginning supplement)	seconds	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Average Gait Speed	Carbidopa Monotherapy and Carbidopa-Levodopa	Gait Speed at Baseline	0.97	Standard Deviation 0.14	meters per second
Average Gait Speed	Placebo	Gait Speed at Baseline	0.86	Standard Deviation 0.18	meters per second
Average Gait Speed	Carbidopa Monotherapy and Carbidopa-Levodopa	Gait Speed Post-Intervention	1.04	Standard Deviation 0.09	meters per second
Average Gait Speed	Placebo	Gait Speed Post-Intervention	0.95	Standard Deviation 0.12	meters per second
Parkinson's Disease (PD)-Cognitive Rating Scale Score	Carbidopa Monotherapy and Carbidopa-Levodopa	Baseline	93.83	Standard Deviation 5.91	score on a scale
Parkinson's Disease (PD)-Cognitive Rating Scale Score	Placebo	Baseline	89.80	Standard Deviation 9.58	score on a scale
Parkinson's Disease (PD)-Cognitive Rating Scale Score	Carbidopa Monotherapy and Carbidopa-Levodopa	Post-Intervention	95.5	Standard Deviation 8.50	score on a scale
Parkinson's Disease (PD)-Cognitive Rating Scale Score	Placebo	Post-Intervention	95.20	Standard Deviation 13.52	score on a scale
Mean of Number of Incorrect Responses on the Stroop Color Word Stepping Test	Carbidopa Monotherapy and Carbidopa-Levodopa	Baseline	0.17	Standard Deviation 0.41	Incorrect Responses
Mean of Number of Incorrect Responses on the Stroop Color Word Stepping Test	Placebo	Baseline	0.8	Standard Deviation 1.79	Incorrect Responses

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Carbidopa Monotherapy and Carbidopa-Levodopa	6
Overall Study	STARTED	Placebo	5
Overall Study	COMPLETED	Carbidopa Monotherapy and Carbidopa-Levodopa	6
Overall Study	COMPLETED	Placebo	5
Overall Study	NOT COMPLETED	Carbidopa Monotherapy and Carbidopa-Levodopa	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events20

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	General disorders	Carbidopa Monotherapy and Carbidopa-Levodopa	1	6
other	Headache	General disorders	Placebo	0	5
other	Blood pressure fluctuations	Cardiac disorders	Carbidopa Monotherapy and Carbidopa-Levodopa	1	6
other	Blood pressure fluctuations	Cardiac disorders	Placebo	0	5
other	Claustrophobia during MRI	Psychiatric disorders	Carbidopa Monotherapy and Carbidopa-Levodopa	1	6
other	Claustrophobia during MRI	Psychiatric disorders	Placebo	0	5
other	Mild Confusion	Psychiatric disorders	Carbidopa Monotherapy and Carbidopa-Levodopa	0	6
other	Mild Confusion	Psychiatric disorders	Placebo	1	5
other	Constipation	Gastrointestinal disorders	Carbidopa Monotherapy and Carbidopa-Levodopa	0	6
other	Constipation	Gastrointestinal disorders	Placebo	1	5

1 to 10 of 20Source ClinicalTrials.gov

See all 20 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Carbidopa Monotherapy and Carbidopa-Levodopa	0	6
Total, all-cause mortality	Placebo	0	5
Total, other adverse events	Carbidopa Monotherapy and Carbidopa-Levodopa	3	6
Total, other adverse events	Placebo	3	5
Total, serious adverse events	Carbidopa Monotherapy and Carbidopa-Levodopa	0	6
Total, serious adverse events	Placebo	0	5

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U01AG061393	Neurobiological drivers of mobility resilience: the dopaminergic system	ROSANO, CATERINA; BOHNEN, NICOLAAS IDA	UNIVERSITY OF PITTSBURGH AT PITTSBURGH	NATIONAL INSTITUTE ON AGING	2018 to 2022

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Carbidopa Monotherapy and Carbidopa-Levodopa vs Placebo: deaths from any cause	Trial comparisons
Carbidopa Monotherapy and Carbidopa-Levodopa vs Placebo: serious adverse events	Trial comparisons

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as
Stroop Color-Word Test	Secondary outcome

Source ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06219915

GET https://conductscience.org/api/trials/v1/NCT06219915/registered

API reference For AI assistants